David CHIRON

Publications :

Toll-like receptors: lessons to learn from normal and malignant human B cell
Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G.
Blood, 15 September 2008, Vol. 112, No. 6, pp. 2205-2213.

Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis
Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G.
The Journal of Immunology, 2009, 183, 4371 -4377

TLR3 Ligand Induces NF-{kappa}B Activation and Various Fates of Multiple Myeloma Cells Depending on IFN-{alpha} Production
Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G.
The Journal of Immunology, 2009, 182, 4471 -4478

Toll-like receptors: expression and involvement in multiple myeloma.
Chiron D, Jego G, Pellat-Deuceunynck C.
Leuk Res. 2010 Dec;34(12):1545-50. Epub 2010 Jul 1. Review.

The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.
Chiron D, Surget S, Maïga S, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.
Br J Haematol. 2012 Mar;156(5):679-83. doi: 10.1111/j.1365-2141.2011.08904.x. Epub 2011 Oct 11.

Modulation of normal and malignant plasma cells function by toll-like receptors.
Jego G, Chiron D, Berthenet K, Pellat-Deceunynck C.
Front Biosci (Elite Ed). 2012 Jan 1;4:2289-301.

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.
Chiron D, Maïga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, Ouiller T, Moreaux J, Klein B, Bataille R, Amiot M, Pellat-Deceunynck C.
Blood Cells Mol Dis. 2012 Apr 15;48(4):247-53. Epub 2012 Feb 15.